 The purpose of this study was to learn how well chloroquine reduces the level of activation of CD8 cells and lowers the levels of bacteria byproducts in people infected with HIV, either off antiretroviral therapy ART protocol version 1.0 dated December 17, 2008 or on-ART protocol version 2.0 dated October 1, 2010. The off-ART Arms A and B and on-ART Arms C and D participants were enrolled during different time periods, and the study was designed to analyze the two study populations separately. This study also looked at how well chloroquine was tolerated and its safety in HIV- infected participants. 